2-(2-phenylethylamino)adenine | 116856-46-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-(2-phenylethylamino)adenine
• 英文别名: 2-(2-Phenylethylamino)-adenine；2-N-(2-phenylethyl)-7H-purine-2,6-diamine
• CAS: 116856-46-3
• 化学式: C₁₃H₁₄N₆
• 分子量: 254.294
• InChiKey: ILQVLBMOQOCNKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  92.5
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氯-6-氨基嘌呤 、 2-苯乙胺 生成 2-(2-phenylethylamino)adenine
  参考文献：
  名称：

  N.sub.9 -cyclopentyl-substituted adenine derivatives useful as adenosine

  摘要：

  该化合物的化学式为I，其中R、R.sub.3和R.sub.5分别独立地表示氢或羟基，但至少其中一个表示羟基；R.sub.1表示氢、低碳基、C.sub.3-C.sub.7-烯基、羟基-低碳基、可选取代的环烷基或可选取代的环烷基-低碳基、双环烷基、双环烷基-低碳基、金刚烷基、四氢吡喃基、四氢硫吡喃基、四氢吡喃基-低碳基、四氢硫吡喃基-低碳基、金刚烷基-低碳基、芳基-羟基-低碳基、芳基、芳基-低碳基、芳基-C.sub.3-C.sub.6-环烷基、9-芴基、9-芴基-低碳基或环烷烯基-低碳基；或R.sub.1表示一个双环苯并5或6-成员饱和碳环基或一个苯并5或6-成员饱和杂环基，所述杂原子选择性地从直接连接到融合苯环上的氧和硫中选择，任何所述双环基在苯基部分上可选择地被低碳基、低烷氧基或卤素取代，或R.sub.1表示任何所述双环基取代-低碳基；R.sub.2表示氢、卤素、--S--R.sub.1 '、--NR.sub.b--R.sub.1 '或--NH--R.sub.1'，其中R.sub.1'具有如R.sub.1所定义的含义，但在--SR.sub.1'中，R.sub.1'不表示氢；R.sub.b表示低碳基；R.sub.4表示羟甲基，但当R.sub.2不表示氢或--NHR.sub.1'时，其中R.sub.1'表示氢或低碳基；或R.sub.4表示低烷氧甲基或低硫代甲基；或R.sub.4表示--CONHR.sub.6，其中R.sub.6表示低碳基、芳基-低碳基、C.sub.3-C.sub.6-环烷基或羟基-低碳基；公认的药物可接受的酯衍生物，其中自由羟基以药物可接受的酯形式酯化；以及其药物可接受的盐；公开了其制备方法；以及其作为腺苷受体激动剂的用途。

  公开号：

  US05063233A1

文献信息

• N.sub.9 -cyclopentyl-substituted adenine derivatives having adenosine-2
  申请人：Ciba-Geigy Corporation

  公开号：US04954504A1

  公开（公告）日：1990-09-04

  The compound of the formula I ##STR1## wherein R, R.sub.3 and R.sub.5 independently represent hydrogen or hydroxy provided that at least one of R, R.sub.3 and R.sub.5 represents hydroxy; R.sub.1 represents hydrogen, lower alkyl, C.sub.3 -C.sub.7 -alkenyl, hydroxy-lower alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, adamantyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyranyl-lower alkyl, tetrahydrothiopyranyl-lower alkyl, adamantyl-lower alkyl, aryl-hydroxy-lower alkyl, aryl, aryl-lower alkyl, aryl-C.sub.3 -C.sub.6 -cycloalkyl, 9-fluorenyl, 9-fluorenyl-lower alkyl or cycloalkenyl-lower alkyl; or R.sub.1 represents a bicyclic benzo-fused 5 or 6-membered saturated cyabocyclic radical or a benzo-fused 5 or 6-membered saturated heterocyclic radical containing a heteroatom selected from oxygen and sulfur directly attached to the fused benzene ring, any said bicyclic radicals being optionally substituted on the benzo portion by lower alkyl, lower alkoxy or halogen, or R.sub.1 represents any said bicyclic radical substituted-lower alkyl; R.sub.2 represents hydrogen, halogen, --S--R.sub.1 ', --NR.sub.b --R.sub.1 ', or --NH--R.sub.1 ' in each of which R.sub.1 ' has meaning as defined for R.sub.1 provided that R.sub.1 ' in --SR.sub.1 ' does not represent hydrogen; R.sub.b represents lower alkyl; R.sub.4 represents hydroxymethyl provided that R.sub.2 does not represent either hydrogen or --NHR.sub.1 ' in which R.sub.1 ' represents either hydrogen or lower alkyl; or R.sub.4 represents lower alkoxymethyl or lower alkylthiomethyl; or R.sub.4 represents --CONHR.sub.6 in which R.sub.6 represents lower alkyl; aryl-lower alkyl, C.sub.3 -C.sub.6 -cycloalkyl or hydroxy-lower alkyl; pharmaceutically acceptable ester derivatives thereof in which free hydroxy groups are esterified in form of a pharmaceutically acceptable ester; and pharmaceutically acceptable salts thereof; methods for their preparation; and their use as adenosine receptor agonists are disclosed.

  本发明涉及一种公式I的化合物：其中R，R3和R5独立地表示氢或羟基，但要求至少有一个R，R3或R5表示羟基；R1表示氢，低碳基，C3-C7-烯基，羟基-低碳基，可选地取代的环烷基或可选地取代的环烷基-低碳基，双环烷基，双环烷基-低碳基，金刚烷基，四氢吡喃基，四氢硫吡喃基，四氢吡喃基-低碳基，四氢硫吡喃基-低碳基，金刚烷基-低碳基，芳基-羟基-低碳基，芳基，芳基-低碳基，芳基-C3-C6-环烷基，9-芴基，9-芴基-低碳基或环烯基-低碳基；或R1表示一个双环苯并5或6-成员饱和的环状基团或一个苯并5或6-成员饱和的含杂原子的杂环基团，所述杂原子从直接连接到融合苯环上的氧和硫中选择，任何所述双环基团在苯基上可选择地被低碳基，低烷氧基或卤素取代，或R1表示任何所述双环基团取代的低碳基；R2表示氢，卤素，-S-R1'，-NRb-R1'或-NH-R1'，其中在每种情况下，R1'的含义如R1所定义，但在-SR1'中，R1'不表示氢；Rb表示低碳基；R4表示羟甲基，但要求R2既不表示氢也不表示-NHR1'，其中R1'表示氢或低碳基；或R4表示低烷氧基甲基或低碳硫基甲基；或R4表示--CONHR6，其中R6表示芳基-低碳基，C3-C6-环烷基或羟基-低碳基；以及其药学上可接受的酯衍生物，其中游离羟基以药学上可接受的酯的形式酯化；以及其药学上可接受的盐；公开了其制备方法；以及其作为腺苷受体激动剂的用途。
• N9-cyclopentyl-substituted adenine derivatives
  申请人：CIBA-GEIGY AG

  公开号：EP0267878A1

  公开（公告）日：1988-05-18

  The compounds of the formula I wherein R, R3 and R5 independently represent hydrogen or hydroxy provided that at least one of R, R3 and R5 represents hydroxy; R1 represents hydrogen, lower alkyl, C3-C7alkenyl, hydroxy-lower alkyl, C3-C6cycloalkyl, C3-C6cycloalkyl-lower alkyl, 2-norbornyl, 2-norbornyl-lower alkyl, aryl, aryl-lower alkyl, aryl-C3-C6cycloalkyl, 9-fluorenyl or 9-fluorenyl-lower alkyl; or R1 represents a bicyclic benzo-fused 5 or 6-membered saturated carbocyclic radical or a benzo fused 5 or 6-membered saturated heterocyclic radical containing a heteroatom selected from oxygen and sulfur directly attached to the fused benzene ring, any said bicyclic radicals being optionally substituted on the benzo portion by lower alkyl, lower alkoxy or halogen; R2 represents hydrogen, halogen, -SR1 or -N(R9)R1 in each of which R1 has meaning as defined hereinbefore provided that R1 in -SR1 does not represent hydrogen; R9 represents hydrogen or lower alkyl; R4 represents hydroxymethyl provided that R2 does not represent either hydrogen or -NHRI in which R1 represents either hydrogen or lower alkyl; or R4 represents lower alkoxymethyl, lower alkylthiomethyl or -CONHR6 in which R6 represents lower alkyl, aryl-lower alkyl, C3-Cscycloalkyl or hydroxy-lower alkyl; pharmaceutically acceptable ester derivatives thereof in which free hydroxy groups are esterified in form of a pharmaceutically acceptable ester; and salts thereof; methods for their preparation; and their use as adenosine receptor agonists are disclosed.

  式 I 的化合物 其中R、R3和R5独立地代表氢或羟基，但R、R3和R5中至少有一个代表羟基；R1代表氢、低级烷基、C3-C7烯基、羟基-低级烷基、C3-C6环烷基、C3-C6环烷基-低级烷基、2-降冰片基、2-降冰片基-低级烷基、芳基、芳基-低级烷基、芳基-C3-C6环烷基、9-芴基或9-芴基-低级烷基；或 R1 代表双环苯并 5 或 6 元饱和碳环基，或苯并 5 或 6 元饱和杂环基，其中含有一个选自氧和硫的杂原子，直接连接到苯并环上，任何上述双环基的苯并部分可选择被低级烷基、低级烷氧基或卤素取代；R2 代表氢、卤素、-SR1 或-N(R9)R1，其中每个 R1 的含义如前文所定义，条件是 -SR1 中的 R1 不代表氢；R9 代表氢或低级烷基；R4 代表羟甲基，条件是 R2 不代表氢或-NHRI，其中 R1 代表氢或低级烷基；或R4代表低级烷氧基甲基、低级烷硫基甲基或-CONHR6，其中R6代表低级烷基、芳基-低级烷基、C3-Cscycloalkyl或羟基-低级烷基；公开了其药学上可接受的酯衍生物，其中游离羟基以药学上可接受的酯的形式酯化；及其盐；其制备方法；及其作为腺苷受体激动剂的用途。
• COMPOUNDS FOR TREATING CYSTIC FIBROSIS
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：US20170362239A1

  公开（公告）日：2017-12-21

  The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).
• US4954504A
  申请人：——

  公开号：US4954504A

  公开（公告）日：1990-09-04
• US5063233A
  申请人：——

  公开号：US5063233A

  公开（公告）日：1991-11-05